Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches.
These growth stocks come from two very different industries. Eli Lilly is riding the GLP-1 drug wave, but there is much more ...
**NM signifies a non meaningful value. A dash signifies the data is not available.